NCT05421442

A Post-marketing Study on the Safety of Abatacept Treatment in Denmark Using the Danish Database

A Nationwide Post-marketing Study on the Safety of Abatacept Treatment in Denmark Using the DANBIO Register

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 38,396 (actual)
• Sponsor: Bristol-Myers Squibb · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to expand on the ongoing post-marketing monitoring of abatacept to include all participants with rheumatoid arthritis (RA) and psoriatic arthritis (PsA) treated with abatacept captured in Danish Database for Biologic Therapies (DANBIO).

Conditions

• Rheumatoid Arthritis (RA)
• Psoriatic Arthritis (PsA)

Timeline

• Start date: 2019-06-13
• Primary completion: 2025-08-22
• Completion: 2025-10-31
• First posted: 2022-06-16
• Last updated: 2025-12-08

Locations

1 site across 1 country: United States